Prostate Cancer

Midwest CEPAC

October 2018 Review

ICER developed a report on anti-androgen drugs for high risk prostate cancer, including the following therapies: enzalutamide (Xtandi®, Astellas and Medivation), abiraterone acetate (Zytiga®, Janssen), apalutamide (Erleada™, Janssen).

Past Reviews

  • September 2009: Active surveillance and Radical prostatectomy 
  • December 2008: Brachytherapy and Proton beam therapy
    Proton beam therapy was also the subject of an evidence review by ICER for the Washington State Health Care Authority in May 2014.
  • November 2007: Intensity modulated radiation therapy (IMRT)

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
September 13, 2018 9am-5pm CT

Chicago Marriott at Medical District/UIC

625 S Ashland Ave

Chicago, IL 60607

The Midwest CEPAC deliberated and voted on evidence presented in ICER's report on anti-androgen drugs for high risk prostate cancer. During this meeting, the Council also discussed ICER's review of treatments for amyloidosis.

Key Dates

Associated Materials

02/16/2018 – 03/07/2018

03/12/2018

Open to public comment until April 2, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.


03/12/2018

03/12/2018 – 04/02/2018

04/09/2018

04/25/2018

05/31/2018

07/12/2018

Open to public comment until August 9, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.



Key Dates

Associated Materials

07/16/2009

09/11/2009

09/11/2009
Other Report Summary

03/04/2010
Other Analysis of New Evidence

Other Materials

Other Evidence Review Group Members

Key Dates

Associated Materials

Other Materials

Other Evidence Review Group Members

Key Dates

Associated Materials

11/23/2007

11/23/2007
Other Report Summary

Other Materials

Other Evidence Review Group Members

Key Dates

Associated Materials

01/21/2016
Other Proven Best Choices